Piramal Healthcare, engaged in manufacturing and sale of own and traded bulk drugs and formulations, reported 17.72 per cent fall in consolidated net profit at Rs 59.87 crore during the third quarter of the current financial year as compared to Rs 72.76 crore in the corresponding last year.
Total income of the company increased from Rs 728.90 crore to Rs 832.60 crore.
On the standalone basis, the company’s net profit for the quarter under consideration slumped by 47.62 per cent at Rs 38.67 crore from Rs 73.82 crore. Total income of the company, however, increased from Rs 489.44 crore to Rs 588.39 crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app